$386 Million is the total value of Opaleye Management Inc.'s 36 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 68.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AXGN | Sell | AXOGEN INC | $72,360,000 | +15.6% | 1,440,000 | -16.0% | 18.73% | +4.6% |
| LOXO | Sell | LOXO ONCOLOGY | $30,359,000 | +46.7% | 175,000 | -2.5% | 7.86% | +32.8% |
| CDXS | Buy | CODEXIS INC | $25,200,000 | +34.7% | 1,750,000 | +2.9% | 6.52% | +22.0% |
| FGEN | FIBROGEN INC | $22,536,000 | +35.5% | 360,000 | 0.0% | 5.83% | +22.7% | |
| BPMC | Sell | BLUEPRINT MEDICINES | $22,218,000 | -59.6% | 350,000 | -41.7% | 5.75% | -63.4% |
| PTE | New | POLARITYTE INC | $18,832,000 | – | 800,000 | +100.0% | 4.87% | – |
| DCPH | Buy | DECIPHERA PHARMACEUTICALS IN | $16,527,000 | +126.0% | 420,000 | +15.1% | 4.28% | +104.6% |
| VKTX | Buy | VIKING THERAPEUTICS INC | $11,388,000 | +136.8% | 1,200,000 | +9.0% | 2.95% | +114.4% |
| SBBP | Buy | STRONGBRIDGE BIOPHARMA PLC | $10,980,000 | -22.0% | 1,830,000 | +15.1% | 2.84% | -29.4% |
| AGIO | AGIOS PHARMACEUTICALS | $10,949,000 | +3.0% | 130,000 | 0.0% | 2.83% | -6.8% | |
| FENC | Buy | FENNEC PHARMACEUTICALS INC | $9,865,000 | -6.6% | 945,000 | +8.2% | 2.55% | -15.4% |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $9,360,000 | +8.4% | 697,500 | +4.9% | 2.42% | -1.9% |
| TGTX | Buy | TG THERAPEUTICS INC | $8,218,000 | +111.1% | 625,000 | +127.9% | 2.13% | +91.1% |
| AMAG | New | AMAG PHARMACEUTICALS INC | $8,190,000 | – | 420,000 | +100.0% | 2.12% | – |
| MGEN | New | MIRAGEN THERAPEUTICS INC | $7,692,000 | – | 1,200,000 | +100.0% | 1.99% | – |
| OCUL | New | OCULAR THERAPEUTIX INC | $7,499,000 | – | 1,111,000 | +100.0% | 1.94% | – |
| MGTA | New | MAGENTA THERAPEUTICS INC | $7,425,000 | – | 550,000 | +100.0% | 1.92% | – |
| BOLD | AUDENTES THERAPEUTICS INC | $7,259,000 | +27.2% | 190,000 | 0.0% | 1.88% | +15.1% | |
| SGMO | Sell | SANGAMO BIOSCIENCES INC | $7,171,000 | -29.5% | 505,000 | -5.6% | 1.86% | -36.1% |
| XOMA | XOMA CORP DEL | $6,685,000 | +3.2% | 320,200 | 0.0% | 1.73% | -6.6% | |
| XNCR | New | XENCOR INC | $6,661,000 | – | 180,000 | +100.0% | 1.72% | – |
| CORI | Sell | CORIUM INTERNATIONAL INC | $6,408,000 | -47.5% | 800,000 | -24.9% | 1.66% | -52.5% |
| CDTX | New | CIDARA THERAPEUTICS INC | $6,240,000 | – | 1,200,000 | +100.0% | 1.62% | – |
| RARE | ULTRAGENYX PHARMACEUTICALS INC | $6,149,000 | +50.7% | 80,000 | 0.0% | 1.59% | +36.5% | |
| PTCT | Buy | PTC THERAPEUTICS INC | $6,071,000 | +54.8% | 180,000 | +24.1% | 1.57% | +40.0% |
| APLS | New | APELLIS PHARMACEUTICALS INC | $5,830,000 | – | 265,000 | +100.0% | 1.51% | – |
| CMRX | Buy | CHIMERIX INC | $5,474,000 | +75.4% | 1,150,000 | +91.7% | 1.42% | +58.9% |
| AMRN | Buy | AMARIN CORP PLCsponsored adr | $5,407,000 | +3.0% | 1,750,000 | +0.3% | 1.40% | -6.9% |
| BFRA | New | BIOFRONTERA AGsponsored adr | $4,755,000 | – | 391,400 | +100.0% | 1.23% | – |
| FOMX | Sell | GTX INC | $3,827,000 | -21.5% | 250,000 | -73.7% | 0.99% | -28.9% |
| EPZM | Buy | EPIZYME INC | $3,726,000 | +200.0% | 275,000 | +292.9% | 0.96% | +171.5% |
| ARQL | New | ARQULE INC | $2,322,000 | – | 420,000 | +100.0% | 0.60% | – |
| PLX | Sell | PROTALIX BIOTHERAPEUTICS INC | $1,333,000 | -24.3% | 3,100,000 | -4.9% | 0.34% | -31.4% |
| CTIC | New | CTI BIOPHARMA CORP | $803,000 | – | 161,400 | +100.0% | 0.21% | – |
| AZRX | New | AZURRX BIOPHARMA INC | $417,000 | – | 130,000 | +100.0% | 0.11% | – |
| BLRX | BIOLINERX LTDsponsored adr | $222,000 | +3.7% | 250,000 | 0.0% | 0.06% | -6.6% | |
| QTNT | Exit | QUOTIENT LTD | $0 | – | -60,000 | -100.0% | -0.08% | – |
| ZSAN | Exit | ZOSANO PHARMA CORP | $0 | – | -100,000 | -100.0% | -0.14% | – |
| SYRS | Exit | SYROS PHARMACEUTICALS INC | $0 | – | -74,074 | -100.0% | -0.28% | – |
| FBIO | Exit | FORTRESS BIOTECH INC | $0 | – | -315,000 | -100.0% | -0.41% | – |
| QTRX | Exit | QUANTERIX CORP | $0 | – | -150,000 | -100.0% | -0.73% | – |
| SNDX | Exit | SYNDAX PHARMACEUTICALS INC | $0 | – | -222,500 | -100.0% | -0.90% | – |
| DEPO | Exit | DEPOMED INC | $0 | – | -600,000 | -100.0% | -1.13% | – |
| ACHN | Exit | ACHILLION PHARMACEUTICALS INC | $0 | – | -1,095,100 | -100.0% | -1.16% | – |
| Exit | ABLYNX NVsponsored adr | $0 | – | -90,000 | -100.0% | -1.40% | – | |
| ARDX | Exit | ARDELYX | $0 | – | -1,135,600 | -100.0% | -1.64% | – |
| Exit | BIOFRONTERA AGsponsored ads | $0 | – | -391,200 | -100.0% | -1.85% | – | |
| Exit | OCULAR THERAPEUTIX INC | $0 | – | -1,111,000 | -100.0% | -2.07% | – | |
| Exit | MIRAGEN THERAPEUTICS INC | $0 | – | -1,060,000 | -100.0% | -2.12% | – | |
| Exit | AMAG PHARMACEUTICALS INC | $0 | – | -420,000 | -100.0% | -2.42% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.